Company profile
LEXICON PHARMACEUTICALS, INC.
NASDAQ:LXRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| INPEFA | approved | $1.1MQ1 2026 | 28 | approved |
| PILAVAPADIN | phase2 | — | 3 | no active trials |
| LX-7101 | phase1_2 | — | 1 | no active trials |
| LX-2931 | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (61)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06203002 | phase2 | completed | 2023-11-29 | 2025-01-14 | Lexicon Pharmaceuticals | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) |
| NCT01494233 | phase2 | completed | 2012-02-01 | 2013-09-01 | Lexicon Pharmaceuticals | A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome |
| NCT02147808 | phase1 | completed | 2014-05-01 | 2014-08-01 | Lexicon Pharmaceuticals | A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects |
| NCT03302845 | phase1 | completed | 2017-09-21 | 2017-10-23 | Lexicon Pharmaceuticals | A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects |
| NCT02531035 | phase3 | completed | 2015-09-01 | 2017-04-01 | Lexicon Pharmaceuticals | A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 216203 | 2023-05-26 | NDA | LEXICON PHARMACEUTICALS INC | |||||
Loading… | ||||||||